Beta Bionics, Inc.

NasdaqGM:BBNX Stock Report

Market Cap: US$1.3b

Beta Bionics Valuation

Is BBNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BBNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BBNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BBNX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BBNX?

Key metric: As BBNX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BBNX. This is calculated by dividing BBNX's market cap by their current revenue.
What is BBNX's PS Ratio?
PS Ratio14x
SalesUS$88.57m
Market CapUS$1.27b

Price to Sales Ratio vs Peers

How does BBNX's PS Ratio compare to its peers?

The above table shows the PS ratio for BBNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average15.2x
SSII SS Innovations International
36.3xn/aUS$1.3b
PRCT PROCEPT BioRobotics
5.7x20.24%US$1.8b
AXGN Axogen
5.2x13.76%US$1.1b
IRMD IRADIMED
13.7x9.95%US$1.1b
BBNX Beta Bionics
14x28.44%US$1.3b

Price-To-Sales vs Peers: BBNX is good value based on its Price-To-Sales Ratio (14x) compared to the peer average (15.2x).

Price to Sales Ratio vs Industry

How does BBNX's PS Ratio compare vs other companies in the US Medical Equipment Industry?

59 CompaniesPrice / SalesEstimated GrowthMarket Cap
XRAY DENTSPLY SIRONA
0.6x1.95%US$2.19b
ENOV Enovis
0.8x5.13%US$1.80b
QDEL QuidelOrtho
0.6x2.96%US$1.49b
IART Integra LifeSciences Holdings
0.6x2.54%US$960.41m
BBNX 14.0xIndustry Avg. 3.2xNo. of Companies59PS03.26.49.612.816+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BBNX is expensive based on its Price-To-Sales Ratio (14x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is BBNX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BBNX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14x
Fair PS Ratio4.4x

Price-To-Sales vs Fair Ratio: BBNX is expensive based on its Price-To-Sales Ratio (14x) compared to the estimated Fair Price-To-Sales Ratio (4.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BBNX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$28.16
US$31.30
+11.15%
10.11%US$35.00US$23.00n/a10
Nov ’26US$27.22
US$31.30
+14.99%
10.11%US$35.00US$23.00n/a10
Oct ’26US$20.21
US$25.33
+25.35%
15.68%US$30.00US$17.00n/a9
Sep ’26US$18.84
US$23.67
+25.62%
19.00%US$30.00US$17.00n/a9
Aug ’26US$16.40
US$23.67
+44.31%
19.00%US$30.00US$17.00n/a9
Jul ’26US$13.94
US$23.56
+68.98%
21.19%US$30.00US$15.00n/a9
Jun ’26US$17.24
US$23.25
+34.86%
22.43%US$30.00US$15.00n/a8
May ’26US$11.14
US$25.71
+130.83%
13.90%US$30.00US$18.00n/a7
Apr ’26US$11.24
US$25.71
+128.77%
13.90%US$30.00US$18.00n/a7
Mar ’26US$20.97
US$26.43
+26.03%
12.93%US$31.00US$20.00n/a7
US$31.3
Fair Value
10.0% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/12 14:51
End of Day Share Price 2025/11/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Beta Bionics, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Travis SteedBofA Global Research
Travis SteedBofA Global Research